KetamineOne Capital said it has appointed Joe Ramelli as its chief financial officer (CFO) effective December 14, 2021, subject to the final acceptance of the NEO Exchange.
Ramelli has nearly 30 years of experience in the public markets and biotechnology, biopharmaceutical and financial services industries, the company said, adding that he specializes in business strategic planning and development, capital raising, talent acquisition, and corporate governance.
“On behalf of the Board of Directors, I am pleased to welcome Joe to Ketamine One (NEO:MEDI.AQN)’s management team as we embark on the company’s exciting next chapter. Mr Ramelli comes to our organization as a highly recommended professional and we are looking forward to learning from his expertise,” said Adam Deffett, Interim CEO of Ketamine One (NEO:MEDI.AQN) in a statement.
READ: Ketamine One Capital reports its first year of revenue generation since going public
Ramelli served as interim CFO at ValenzaBio, a privately-held biopharmaceutical company, where he established and grew all the finance functions of the company. He holds a Bachelor of Arts in business economics from the University of California, Santa Barbara.
He replaces Peter Nguyen who has amicably agreed to depart the company. Nguyen also resigned from the company’s board, effective December 13, 2021.
“I would like to thank Peter for his service to Ketamine One (NEO:MEDI.AQN) and I appreciate his efforts to help the company become a public issuer. I and the team wish him well on his future endeavors,” added Deffett.
Ketamine One (NEO:MEDI.AQN) also said it intends to confidentially submit a draft registration statement on Form S-1 to the US Securities and Exchange Commission relating to a potential $20 million initial public offering of its common shares in the United States.